Episurf Medical receives expanded reimbursement coverage in the UK, Netherlands and Belgium
In line with Episurf Medical’s plan to achieve private health sector reimbursement, the Episealer® procedure and products have been approved for payment in the UK Spire Hospitals and the Dutch health insurance companies, VGZ and Multiorg. This means that surgeons wishing to perform the Episealer® procedure are approved to operate and the procedure and devices will be paid for.
Further, the Belgium reimbursement authority RIZIV – The National Institute for Health and Disability Insurance – has approved the Episealer® Femoral Twin implant. This means the entire Episealer® Portfolio comprising Condyle Solo, Trochlea Solo and Femoral Twin is now approved for payment by the Belgium authority.
“Reimbursement approval across public and private healthcare providers is a key factor in driving surgical adoption and product sales across our European markets”, says Rosemary Cunningham Thomas, CEO of Episurf Medical.
“We have an ongoing plan underway to ensure we obtain country specific reimbursement in our key geographies”, concludes Rosemary Cunningham Thomas.
For more information, please contact:
Rosemary Cunningham Thomas, CEO, Episurf Medical
Tel: +46 (0) 70-7655892
Tel: +44 (0) 7803-753603
rosemary@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.
Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.
